We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aurora Cannabis (ACB) Soars 6.2%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Aurora Cannabis Inc. (ACB - Free Report) shares rallied 6.2% in the last trading session to close at $6.17. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 20% gain over the past four weeks.
The sharp upsurge in Aurora Cannabis shares can be attributed to a sector-wide wave of optimism surrounding potential U.S. regulatory easing and renewed political support for cannabis reform, which reignited investor sentiment across the industry. Hopes of marijuana rescheduling, expected to unlock better banking access and tax treatment for cannabis firms, combined with recent high-profile endorsements of CBD by prominent policymakers, fueled broad buying momentum. This convergence of policy optimism and positive media coverage drew fresh institutional and retail interest toward established names like Aurora Cannabis.
This company is expected to post quarterly earnings of $0.03 per share in its upcoming report, which represents a year-over-year change of -25%. Revenues are expected to be $63.79 million, up 7.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Aurora Cannabis, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ACB going forward to see if this recent jump can turn into more strength down the road.
Aurora Cannabis belongs to the Zacks Medical - Products industry. Another stock from the same industry, Bio-Rad Laboratories (BIO - Free Report) , closed the last trading session 4.1% lower at $296.52. Over the past month, BIO has returned 6.5%.
For Bio-Rad, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $2.25. This represents a change of +11.9% from what the company reported a year ago. Bio-Rad currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Aurora Cannabis (ACB) Soars 6.2%: Is Further Upside Left in the Stock?
Aurora Cannabis Inc. (ACB - Free Report) shares rallied 6.2% in the last trading session to close at $6.17. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 20% gain over the past four weeks.
The sharp upsurge in Aurora Cannabis shares can be attributed to a sector-wide wave of optimism surrounding potential U.S. regulatory easing and renewed political support for cannabis reform, which reignited investor sentiment across the industry. Hopes of marijuana rescheduling, expected to unlock better banking access and tax treatment for cannabis firms, combined with recent high-profile endorsements of CBD by prominent policymakers, fueled broad buying momentum. This convergence of policy optimism and positive media coverage drew fresh institutional and retail interest toward established names like Aurora Cannabis.
This company is expected to post quarterly earnings of $0.03 per share in its upcoming report, which represents a year-over-year change of -25%. Revenues are expected to be $63.79 million, up 7.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Aurora Cannabis, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ACB going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Aurora Cannabis belongs to the Zacks Medical - Products industry. Another stock from the same industry, Bio-Rad Laboratories (BIO - Free Report) , closed the last trading session 4.1% lower at $296.52. Over the past month, BIO has returned 6.5%.
For Bio-Rad, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $2.25. This represents a change of +11.9% from what the company reported a year ago. Bio-Rad currently has a Zacks Rank of #3 (Hold).